Evidence map›Paper›PMID 27868409›Full record

ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2016

[Effect of RAD18-siRNA on proliferation and chemotherapy sensitivity of human esophageal squamous cell carcinoma ECA-109 cells].

Pengrong Lou, Xiaonan Sun, Jundong Zhou, Shitao Zou

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Pengrong LouDepartment of Radio-Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310020, China;Department of Radio-Oncology, Ningbo First Hospital, Ningbo 315010, China.
Xiaonan SunDepartment of Radio-Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310020, China. sunxiaonan@hotmail.com.
Jundong ZhouDepartment of Radio-Oncology, Suzhou Municipal Hospital, Nanjing Medical University, Suzhou 215001, China. zhoujundong330@163.com.
Shitao ZouSuzhou Cancer Center Core Laboratory, Suzhou Municipal Hospital, Nanjing Medical University, Suzhou 215001, China.
Sir Run Run Shaw Hospital · CNSuzhou Municipal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adjuvants, PharmaceuticCarcinoma, Squamous CellCell CycleCell Line, TumorCell ProliferationCisplatinCyclin D1DNA-Binding ProteinsDown-RegulationDrug Resistance, NeoplasmDrug Screening Assays, AntitumorDrug SynergismEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFluorouracilG1 PhaseAdjuvants, PharmaceuticCCND1 protein, humanCisplatinCyclin D1DNA-Binding ProteinsFluorouracilRAD18 protein, humanRNA, Small InterferingUbiquitin-Protein Ligases

Identifiers

PMID27868409
PMCPMC10400814
OpenAlexW2554080121

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.